NFE2L2 and neoplasm: Moreover, it is worth emphasizing the noteworthy observation that myeloid‐derived suppressor cells (MDSCs) represent an immunosuppressive cellular subset within the tumor microenvironment (TME),[29] and abrogation of their NRF2 signaling instigates a reprogramming of MDSCs from an immunosuppressive phenotype to one that promotes the efficacy of CTLs.[30, 31] These findings underscore the promising potential of targeting NRF2 signaling as a valuable therapeutic strategy to enhance PDT efficiency and reverse immune tolerance.